{"doi":"10.1001/jamanetworkopen.2025.31189","title":"Personalized High-Definition Transcranial Direct Current Stimulation for the Treatment of Depression","abstract":"Importance: Transcranial direct current stimulation (tDCS) shows promise for treating depression. The precision and focality of stimulation may influence therapeutic outcomes; thus, investigation of personalized focal high-definition (HD) tDCS for treating depression is needed. Objective: To determine whether HD-tDCS therapy can improve mood in patients with moderate to severe depression. Design, Setting, and Participants: This randomized clinical trial used a double-blind, sham-controlled, parallel study design. The trial was conducted from December 1, 2020, to March 7, 2024, at UCLA. Each participant received a 4-week follow-up. Participants were required to meet diagnostic criteria for a current major depressive episode (evaluated using the Mini International Neuropsychiatric Interview), present moderate to severe depressive symptoms (ie, have a 17-item Hamilton Depression Rating Scale [HAMD] score ≥14 and <24), be either treatment naive or receiving a stable standard antidepressant regimen, and be 18 to 65 years of age. Key exclusion criteria included treatment-resistant depression, bipolar disorder, or schizophrenia. Of 560 volunteers screened, 71 were found to be eligible for participation. Interventions: Participants received 20 minutes of active or sham HD-tDCS each day for 12 consecutive working days. Structural magnetic resonance imaging and frameless stereotaxic neuronavigation were used to personalize the HD-tDCS configuration to each participant. Main Outcomes and Measures: Pretreatment to posttreatment change in the HAMD score. Results: Seventy-one participants (44 female [62.0%]; mean [SD] age, 34.3 [10.4] years) were randomized to receive active (n = 40) or sham (n = 31) HD-tDCS therapy. The primary outcome measure, mean (SD) pretreatment to posttreatment change in HAMD score, differed significantly between treatment groups (group difference, -2.2 [4.3]; P = .04; Cohen d, -0.50 [95% CI, -0.99 to -0.01]). Post hoc 2-sample t tests revealed significant decreases in HAMD scores within both groups, with (significantly) greater decreases in the active treatment group (active HD-tDCS group, -7.8 [4.2]; sham HD-tDCS group, -5.6 [4.4]). HD-tDCS was well-tolerated, with mild to no adverse effects. Exploratory analyses indicated a significant active treatment-related improvement in the anxiety dimension of the primary outcome measure (group difference, -0.68 [1.42]; P = .049; Cohen d, -0.48 [95% CI, -0.96 to -0.004]). Conclusions and Relevance: In this randomized clinical trial of HD-tDCS in participants with moderate to severe depression, the 12-day HD-tDCS therapy was observed to significantly improve mood with a moderate effect size. Similar effect sizes in pharmacotherapy, psychotherapy, and conventional tDCS-based therapy have been observed to occur substantially later, highlighting the clinical potential of more precise and focal tDCS in depression. Follow-up studies with appropriate maintenance treatments are needed to clarify the persistence of antidepressant effects, as well as possible therapy optimizations. Exploratory analyses indicated that HD-tDCS therapy also may be salient for treating anxiety disorders. Trial Registration: ClinicalTrials.gov Identifier: NCT04507243.","journal":"JAMA Network Open","year":2025,"id":514035,"datarank":0.46107722909076543,"base_score":2.302585092994046,"endowment":2.302585092994046,"self_citation_contribution":0.3453877639491069,"citation_network_contribution":0.11568946514165854,"self_endowment_contribution":0.3453877639491069,"citer_contribution":0.11568946514165854,"corpus_percentile":null,"corpus_rank":null,"citation_count":9,"citer_count":9,"citers_with_citation_signal":4,"citers_with_endowment":4,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9651,"is_data_producer":true,"deposit_databanks":{"ClinicalTrials.gov":["NCT04507243"]},"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1376581,"name":"Vera Norris","orcid":null,"position":1,"is_corresponding":false},{"id":1376582,"name":"Paloma Pfeiffer","orcid":null,"position":2,"is_corresponding":false},{"id":891815,"name":"Brandon Taraku","orcid":"0000-0001-7998-1128","position":3,"is_corresponding":false},{"id":1376583,"name":"Suzanne Kozikowski","orcid":null,"position":4,"is_corresponding":false},{"id":1376584,"name":"Jacquelyn Schneider","orcid":null,"position":5,"is_corresponding":false},{"id":466596,"name":"Michael Boucher","orcid":null,"position":6,"is_corresponding":false},{"id":706172,"name":"Marco Iacoboni","orcid":"0000-0002-0035-5413","position":7,"is_corresponding":false},{"id":1376585,"name":"Roger Woods","orcid":null,"position":8,"is_corresponding":false},{"id":314811,"name":"Katherine L. Narr","orcid":"0000-0002-9396-7936","position":9,"is_corresponding":false},{"id":412110,"name":"Mayank Jog","orcid":"0000-0003-2519-1192","position":0,"is_corresponding":true}],"reference_count":62,"raw_metadata":null,"created_at":"2026-07-19T02:48:23.284782Z","pmid":"40932717","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}